Speakers

Eamonn Warren serves as Group Vice President of API and Dry Products Manufacturing at Eli Lilly and Company, where he leads the global network of internal and external manufacturing sites responsible for active pharmaceutical ingredients and dry-product production. He assumed this role in 2024 and is a member of Lilly’s Manufacturing Leadership Team.

Eamonn began his career with Lilly in 1995 at the Kinsale manufacturing site in Ireland as an automation engineer. Over the course of nearly three decades, he has held roles of increasing responsibility across engineering, operations, Six Sigma, human resources, and site leadership. His international experience includes assignments in Puerto Rico, Indianapolis, Augusta in the state of Georgia, and the Fegersheim manufacturing site in France.

Prior to his current position, Eamonn served as the global lead for Lilly’s Parenteral Manufacturing Network, where he oversaw strategy, performance, and modernization across Lilly’s sterile manufacturing capabilities. He is recognized for championing advanced and innovative manufacturing approaches as well as for his focus on operational excellence, talent development, and regulatory rigor.

A native of Ireland, Eamonn holds a degree in Chemical Engineering from University College Dublin and a degree in Management and Marketing from University College Cork.

Dr Mire-Sluis is currently Head of Quality for Gilead Sciences. He was Head of Global Quality for AstraZeneca and Vice President, North America, Singapore, Contract and Product Quality at Amgen Inc. He was previously Principal Advisor, Regulatory Science and Review, Office of Biotechnology Products, CDER and Head of Analytical Sciences and Standards, Office of the Director, CBER, FDA, in Bethesda, Maryland.

He trained in Genetics and Biometry and has a PhD in Cell biology and Biochemistry. Dr Mire-Sluis was the Head of the Cytokine Group in the Division of Immunobiology at the National Institute for Biological Standards and Control, Potters Bar, UK. Dr Mire-Sluis specialized in the development of assays for the characterization and quantitation of biological products. He then became Director of BioAnalytical Sciences at Genentech and prior to joining FDA, was Executive Director of Analytical Sciences at CancerVax Corporation, San Diego.

Joanne is a seasoned biotech executive with over 30 years of experience across large pharma and early-stage biotech in the areas of operations, leadership, product development, process development, clinical & commercial manufacturing, and supply chain. Over the course of her career, she has contributed to the licensure and commercialization of numerous medicines across different modalities and therapeutic areas. She has fostered high-performing, empowered individuals and teams and mutually beneficial partnerships with both internal and external stakeholders.

Before Halozyme, Joanne most recently served as the Chief Technical Officer at Abata Therapeutics, a company developing Treg cell therapies for serious autoimmune and inflammatory diseases.  Prior to Abata, she served as the Chief Technical Officer at Aerium Therapeutics, Inc. and as the Chief Operating Officer and interim CEO at Boston Pharmaceuticals. Previously, Joanne served as the Executive Vice President of Global Pharmaceutical Development and Operations at Celgene Corporation where she oversaw the company’s Product Development, Global Manufacturing Operations, Supply Chain, Engineering and Quality functions. Joanne also served in leadership positions at other pharmaceutical and biotech companies, including Shire, Abbott Laboratories, Amgen, and Genentech. She has served as a member of the Board of Directors of public biopharmaceutical companies, including Orchard Therapeutics and Astria Therapeutics.

Joanne holds a Ph.D. in Biochemistry and Molecular Biology from Oregon Health and Science University and completed a postdoctoral fellowship in the department of Pharmaceutical Chemistry at the University of California, San Francisco.

Anne Kantardjieff, PhD, is Vice President and Head of CMC Development and Regulatory for Biologics and Advanced Therapies at Biogen. She is a seasoned biopharmaceutical executive with over 15 years of experience advancing complex biologics and cell and gene therapies from early development through global commercialization.

Anne is recognized across the industry for her expertise in CMC strategy, manufacturing scalability, and regulatory integration for advanced modalities. She leads global teams responsible for development, technical transfer, and regulatory CMC strategy across a diverse portfolio of biologics and ATMP programs, partnering closely with R&D, Quality, and Commercial Operations to enable reliable, inspection-ready supply and accelerated patient access.

Prior to Biogen, Anne served as Vice President of Manufacturing and MSAT at bluebird bio, where she led end-to-end supply and technical operations for four commercially approved autologous gene therapies—Zynteglo, Skysona, Abecma, and Lyfgenia. In this role, she oversaw external manufacturing partnerships, process validation, regulatory inspections, and commercial launch execution across multiple global markets.

Earlier in her career at bluebird bio, Anne drove strategic process improvements, expanded manufacturing capacity, and played a pivotal role in successful product approvals. She previously held leadership roles at Alexion Pharmaceuticals, where she led early- and late-stage process development teams and contributed to the commercialization of Strensiq, Kanuma, and Ultomiris.

Anne is known for building high-performing, collaborative organizations and integrating technical rigor with strategic decision-making to modernize manufacturing platforms and enable modality agility.

She holds a PhD in Chemical Engineering from the University of Minnesota and a Bachelor of Engineering in Chemical Engineering from McGill University. She is widely published and has held leadership roles within the American Chemical Society’s Biochemical Technology Division.

Hilary Marston, M.D., M.P.H., served for more than a decade as a leader and strategic advisor on national public health policy and is a recognized expert in the clinical and regulatory aspects of medical product and vaccine development. She brings this expertise to her work with biotechnology and drug companies and investors at Canal Row, and prior to this, at Marston Health, LLC, which she founded after her tenure in FDA leadership. 

Dr. Marston was FDA’s inaugural Chief Medical Officer, serving as the primary clinical advisor to the Commissioner and leading the office that oversees clinical matters involving multiple FDA product development centers, including financial incentives (e.g., for rare disease product development), targeted grantmaking, and research participant protection policy. She also led the Agency’s response to health crises, including epidemics and medical product shortages.

Dr. Marston previously served as Senior Advisor for Global COVID-19 Response on the White House COVID-19 Response Team, as Director for Medical Biopreparedness and Response at the U.S. National Security Council, and as Policy Advisor for Pandemic Preparedness at the National Institute of Allergy and Infectious Diseases. She also worked at McKinsey & Company and the Bill & Melinda Gates Foundation.

Dr. Marston trained in Internal Medicine and Global Health Equity at Brigham & Women’s Hospital. She completed her M.P.H. at the Harvard School of Public Health.

Anders Vinther, founder of Quality Business Administration, is a well-known and respected quality leader in the pharmaceutical industry. He has founded, grown, and merged companies, led company culture, financial and compliance turnarounds, and helped many people developing their career.

Anders founded QBA to educate and develop experts and leaders in the pharmaceutical industry to become better Quality Business Leaders and for the Quality Function to become a core business competency. He is currently collaborating with the University of Dublin to realize his dream of a Quality Business Leader Certification Program.

Anders is a Danish and USA citizen and has worked with and in many cultures. He has held many global senior leadership roles in large and small companies including Sanofi, Genentech, Roche, Novo Nordisk, AGC Biologics, Intarcia, Kronos Bio. For more than 25 years Anders has also been active in developing the Quality function as a more active stakeholder in public health activities.

Anders is a multi-passionate entrepreneur. He is founder of CMC Biologics (now AGC Biologics), Quality Business Administration, and Flying Suitcase Wines, an award-winning winery where he is the winemaker.

Jason Martin is the Senior Vice President and Head of Technical Operations at Halozyme, overseeing manufacturing, supply chain, quality, MS&T, operations, facilities, EHS, and information security functions. He played a pivotal role in developing Halozyme’s global manufacturing strategy for the Hypercon™ Formulation Technology Platform, securing $112M in Series C funding, and supporting the company’s $900M acquisition by Halozyme. With over 28 years of global biopharmaceutical experience, Jason has led strategic initiatives across startups, turnarounds, and product launches from clinical to commercial supply. His career includes leadership roles at Bristol Myers Squibb in cell therapy operations, Novartis in external supply and product launches, and Merck in technical operations, where he contributed to the commercialization of products such as Gardasil®, Abecma®, Breyanzi®, Zarxio™, and Glatopa®. He is passionate about advancing novel technologies to improve patient health worldwide.

Jasmine Riley is Head of Global Compliance within Thermo Fisher Scientific’s Patheon (PSG) network, where she leads global GMP compliance strategy across a diverse portfolio of sterile, biologics, and drug product manufacturing sites. In this role, she partners with site leadership and regulators to ensure sustained inspection readiness, drive quality culture, and oversee complex regulatory response strategies across FDA, EMA, and other global health authorities.

With over two decades of experience in pharmaceutical and biopharmaceutical manufacturing, Jasmine brings deep expertise in sterile and aseptic operations, regulatory remediation, data integrity, and inspection management. She has extensive experience supporting and leading global health authority inspections, including serving as a primary compliance representative during critical regulatory interactions and overseeing FDA 483 and warning letter response strategies.

Prior to joining Thermo Fisher Scientific, Jasmine held senior leadership roles at Merck, Novartis, and AstraZeneca, where she led global quality assurance, GMP auditing, and compliance remediation initiatives across biologics, vaccines, and contract manufacturing networks. Her work has consistently focused on strengthening quality systems, mitigating compliance risk, and enabling sustainable operational excellence.

Jasmine holds a Master of Jurisprudence in Pharmaceutical and Compliance Law from Seton Hall Law School and a Bachelor of Science in Biochemistry from Howard University. She is passionate about advancing compliance as a strategic enabler of innovation and patient safety across the pharmaceutical industry.

Dr. Thirumoorthy has 20 years of experience in the pharmaceutical industry, including in cell therapies, with expertise in technical operations, chemistry, Manufacturing and Control (CMC), quality control and quality assurance/compliance.

Before joining AstraZeneca, she spent 3 years at Neogene building the Technical operations team of experienced leaders to handle TCR products from pre-IND onwards. She spent six years at Kite Pharma, where she was part of the team to take Yescarta and Tecartus from pre-IND to BLA and launch. Prior to Kite Pharma, she was Principal, Quality Control and Assurance, at Quality Systems Solutions. She also held positions in Quality Assurance and Quality Control. She began her career in biopharma as a Senior Scientist/Group Leader, Research & Development, at PPD Development.

Dr. Thirumoorthy earned a B.Sc. in chemistry from the University of Madras in India, an M.S. and Ph.D. in chemistry from the Indian Institute of Technology in Madras and was a Post-Doctoral Research Associate at the University of Illinois in Chicago and Urbana.

Frank was awarded his PhD in Synthetic Organic Chemistry at Imperial College London and completed Post Doctoral studies at Ohio State University.  He started his career at AstraZeneca in the Chemical Development function for 13 years before switching to CMC Regulatory Affairs.  Frank now leads the CMC Regulatory group in AstraZeneca responsible which is responsible for all AZ product from development across the whole product lifecycle.  Frank and his team are heavily involved in regulatory advocacy to  deliver faster access to medicines, having been directly engaged with International regulatory guideline development through ICH and working with numerous health authorities across the globe.

Vaishali Shukla is a proven leader with expertise in quality and in developing the teams required to deliver it.

In her current role as VP, of Quality at Lilly, Vaishali leads new API manufacturing sites. In this role, Vaishali oversees functional and site strategies, setting overarching goals and objectives as well as developing and executing short- and long-term strategic direction.

With more than 20 years of experience in the biopharmaceutical industry, she is an expert in a broad variety of subjects ranging from early clinical development to commercialization of Cell and Gene therapy, Peptide, ADC, biologics & small molecules.

Vaishali’s career includes work at BioVest International, Takeda Pharmaceuticals, Shire Pharmaceuticals, UniQure, and Kite where she implemented novel processes for continuous development.

With a BS in Biology, master’s degrees in Botany, Regulatory Affairs, Pharmaceutical Economics and Policy, and a Ph.D. in Pharmaceutical Science.

Vaishali lives in the Indianapolis area and is the proud mother of her daughter Smita, who is following her footsteps as a female trailblazer in the biosciences.

Ben Parkhurst is Senior Director, CMC Lead at Pioneering Medicines, a Flagship Pioneering initiative, where he leads CMC strategy across a portfolio of therapeutic programs spanning multiple modalities, developed with Flagship companies and external partners through Flagship’s Innovation Supply Chain. He also drives operational and digital initiatives across the broader TechOps organization.

Ben brings 15 years of CMC and drug development experience. Prior to Flagship, he served as Director of Manufacturing Sciences & Technology at Generation Bio, leading development, and manufacturing of a novel ceDNA-LNP platform. Earlier in his career, he played a key role in establishing uniQure’s GMP gene therapy operations and supported commercial-scale manufacturing at Cubist Pharmaceuticals.

Ben is an SME in Project Artemis, an industry consortium digitalizing CMC. He is pursuing an MBA at the MIT Sloan School of Management, Class of 2027, and holds a Master’s in Bioengineering from Tufts University and a Bachelor’s in Biomedical Engineering from WPI.

Jonathan Chapman, MS, is the Global Head of Quality Compliance and Audits at Gilead Sciences, where he oversees global inspection management and the GMP/GDP audit program supporting quality and compliance across the company’s global supply chain.

Prior to joining Gilead, Jonathan spent over a decade at the U.S. Food and Drug Administration (FDA), where he conducted domestic and international inspections, managed and mentored teams of FDA investigators, and served as a policy advisor on both domestic and international regulatory matters. He is a former U.S. Diplomat, having served as Assistant Country Director in FDA’s Beijing, China Office from 2018 to 2023, where he supported FDA’s international regulatory engagement and oversight efforts.

Mark Keegan is the Global Head of Drug Substance Process Development & Industrialization at Sanofi’s mRNA Center of Excellence, where he leads a global team advancing mRNA process development for multiple vaccines and therapeutics in clinical development. Under his leadership, the team has successfully scaled mRNA processes to commercial scale and completed tech transfer to GMP manufacturing facilities.

With over 25 years of biotech experience, Mark has built a distinguished career at the intersection of particle technology and biologics — spanning mRNA, oligonucleotides, proteins, and small molecules. Prior to Sanofi, Mark held senior leadership positions at Translate Bio, Tidal Therapeutics, and Selecta Biosciences, where he consistently delivered innovative solutions for scaling novel biologics from laboratory to commercial manufacturing. He holds a B.S. in Chemical Engineering from Brown University and an M.S. in Engineering from Northeastern University.

Katelyn Hahn is an experienced supply chain leader specializing in pharmaceutical supply chain strategy with extensive expertise in end-to-end supply chain management, manufacturing analysis, production planning, and procurement services. Her background includes leadership roles in major consumer, OTC and pharmaceutical companies, focusing on optimizing supply plans, driving process improvements, and managing global procurement.

• Leadership in Supply Chain Strategy
• Site and Production Planning Expertise
• Global Procurement and Supplier Management
• Supply Continuity and Process Improvement

Brian Curran oversees the success of MasterControl’s Manufacturing Excellence (Mx) solution in the quest to digitize the 80% of life sciences manufacturing, large and small, that still use paper for their batch records or device history records. Curran has the privilege of working externally with Mx customers and internally across MasterControl from R&D to sales, services, and support to ensure Mx success and adoption.

Curran joined MasterControl in 2002 to direct and expand MasterControl’s product lines. In 2017 he switched to focus on bringing Mx to market, which happened mid-2019 and now has well over 100 customers who have completed hundreds of thousands of production records.

Curran began his career with IBM, where he led consulting engagements with Fortune 500 companies, such as MCI, Bellsouth, and others. After this he held several director and VP level product management positions for software companies serving the telecommunications and web analytics sectors. Curran has an MBA with an information systems emphasis.

Allison Cacciatore serves as Vice President of Technical Operations at Project Farma, where she leads manufacturing operations and capital project execution across cGMP-regulated pharmaceutical environments. In this role, Allison partners with clients to ensure facility and equipment readiness, operational reliability, and regulatory compliance across complex manufacturing programs.

Allison brings more than 20 years of experience in pharmaceutical manufacturing and operations, with deep expertise in facility and equipment readiness, regulatory inspections, and large-scale capital project execution. She has served as the primary interface with global health authorities and has led multimillion-dollar capital initiatives supporting both new construction and renovation of cGMP facilities.

She holds a Bachelor of Science in Chemical Engineering and an MBA in Management from Lehigh University and brings a hands-on, execution-focused approach to supporting compliant manufacturing operations.

Scott May, Ph.D. currently serves as Vice President of Chemistry in Synthetic Molecule Design and Development (SMDD) at Eli Lilly and Company. He earned a B.S. in Chemistry from Hope College (’93) and a Ph.D. in Organic Chemistry from Indiana University (’98). Scott’s passion for exploring new chemistry and his strong advocacy for implementation of novel, enabling technologies has been a constant theme throughout his 26+ years at Lilly. Scott has championed Lilly’s development efforts in Continuous Manufacturing and Oligonucleotide Synthesis. His efforts to drive the integration of new technologies within Lilly has led to new facilities within development, manufacturing, and at external partners. Scott’s most recent work is focused on transforming the manufacturing of oligonucleotide therapeutics to reduce costs, environmental impact, and allow broad patient access to the most cutting-edge medicines in the Lilly portfolio.

Sue Marrichi is the site head of Ultragenyx’s Gene Therapy Manufacturing Facility (GTMF) located in Bedford, MA. The greenfield site was opened in 2023 and is operational for clinical and commercial manufacture of gene therapies. Prior to becoming site head, Sue led the Gene Therapy Engineering, Facilities, and Validation teams in the design, buildout, and startup of the GTMF, as well as the GMP QC laboratories in Woburn, MA. Before joining Ultragenyx, Sue received her bachelor’s and master’s degrees in Chemical and Biomolecular Engineering from Cornell University, and went on to work at Regeneron, Allergan, Shire, and Takeda in various technical and leadership roles across biopharmaceutical development and manufacturing. With over 20 years in industry, Sue is a leader who is passionate about building an inclusive culture that results in high functioning teams who are ultra committed to delivering treatments to rare disease patients.

Paresma (Pinky) Patel, Ph.D. is Director of Regulatory CMC Policy & Advocacy at Gilead Sciences, where she leads chemistry, manufacturing, and controls (CMC) regulatory advocacy in support of global health authority filings. In this role, she represents Gilead in multiple external forums and advances regulatory policy initiatives, including implementation of ICH M4Q (R2), ICH Q12, and evolving assessment standards.

Prior to joining Gilead, Dr. Patel spent a decade at the U.S. Food and Drug Administration (FDA) (2015–2025), holding positions of increasing responsibility within CDER’s Office of Pharmaceutical Quality. Her roles included Reviewer, Branch Chief, and ultimately Division Director in the Office of Product Quality Assessment III. As Division Director, she led teams responsible for the evaluation of CMC information, with a primary focus on drug substance quality across all stages of development. During her FDA tenure, she also contributed to numerous strategic initiatives and the development of regulatory policies and guidelines.

Earlier in her career, Dr. Patel worked as a medicinal chemist at the National Institutes of Health. She earned her Ph.D. in Organic Chemistry from The Scripps Research Institute (2010) and completed a postdoctoral fellowship at the California Institute of Technology (2012).

Vinod Bulusu leads Products team in Global Technical Operations (GTO) and provides CMC leadership in Operations for Biologics modalities at AstraZeneca. Vinod, has about 20 years’ experience in commercializing biologics. Prior to AstraZeneca, Vinod worked at PwC as a management consultant and at Amgen led late stage process development and technology transfers. Vinod has a Masters in Chemical Engineering and an MBA.

Jacob Greenwood has spent his 15+ year professional career working in the Life Sciences industry. At Project Farma, Jacob is a strategic leader, creating and fostering client relationships and building brand awareness within the pharmaceutical and biotech industries.

In addition to his experience with Project Farma, Jacob spent 5 years as a business development professional within the Architecture, Engineering, and Construction industry, delivering projects totaling nearly $500M. Prior to developing his sales career, he was an active member of the preclinical research community, managing vivariums in both Maryland and North Carolina. Jacob remains committed to helping medicines and therapies move through the research and development stage into manufacturing and ultimately into a position to positively impact the lives of patients.

Ignacio Nunez is an accomplished executive in the life sciences and advanced materials industries, with extensive expertise in biologics, cell and gene therapies, and complex manufacturing systems.

As the Former Chief Operations Officer of CellReady, Ignacio has driven the company’s operational expansion in the cell and gene therapy sector, focusing on next-generation medicines and strategic execution across partnerships with global biologics companies, startups, academic institutions, financial investors, and CDMOs/CROs. His leadership has enabled large-scale organizational transformations, delivering substantial reductions in capital expenditure and development timelines while strengthening GMP manufacturing, quality, and supply chain performance.

Previously, Ignacio played a key role in pioneering the industrialization of next-generation therapies, contributing to the commercialization of several of the first FDA-approved cell and gene therapies. He also founded BioExcellence, where he developed a high-throughput manufacturing model adopted to design and optimize some of the world’s largest cell therapy production facilities.

Ignacio holds B.S. and M.Sc. degrees in Chemical Engineering from the University of Granada and is a certified Lean Six Sigma Master Black Belt.

Andrew Jacon is a Sales leader in industrial software, with a strong focus on pharma MES, digital transformation, and driving real-world adoption. He works closely with global life sciences teams to turn complex manufacturing challenges into practical, scalable business results.

Pierrick Lebigre is Vice President Product Software at Körber Business Area Pharma, where he leads the product direction for the company’s industry-leading software solutions, including the PAS-X Manufacturing Execution System (MES). He brings over a decade of hands-on experience deploying MES solutions for the pharma and biotech industry, having held roles spanning Consultant, Functional and Technical Lead, and Project and Program Manager. In his current leadership position, Pierrick drives Körber’s vision of cloud- and AI-powered digital manufacturing, helping life sciences companies modernize their shopfloor operations and build sustainable competitiveness in highly regulated environments.

Rainer Haemmerle is the Executive Director of Manufacturing at Boehringer Ingelheim Fremont Inc., where he leads end-to-end commercial biologics manufacturing for U.S. Biopharma. With over two decades of experience at Boehringer Ingelheim, Rainer has held leadership roles in Contract Manufacturing, including Director of Commercial Manufacturing in Shanghai, China, and key positions in Quality Operations and Biologics Production in Vienna, Austria. His career has been marked by the successful launch of numerous biologic molecules worldwide, as well as spearheading initiatives in human error reduction, leadership development, and major CAPEX expansion projects. Rainer holds a master’s degree in biology from the University of Vienna, Austria, with research experience at Universidad Autónoma (Spain), Universidade de Brasília (Brazil), and the Weizmann Institute (Israel).

Bart Reitter is Vice President of Sales for the Americas at Honeywell Life Sciences, and a seasoned veteran with over 30 years of experience in the enterprise software and Life Sciences industries. He is responsible for directing sales strategy and driving revenue growth for Honeywell’s portfolio of advanced SaaS and AI solutions across the Americas. His career is marked by expertise in leveraging technology to enhance operational efficiency and maintain regulatory compliance within the Life Sciences sector.

Prior to joining Honeywell, he served as Vice President of Sales for QAD as well as leading a global P&L focused on Life Sciences, where he was responsible for global strategy, solution positioning and product development.

He previously oversaw global marketing for a leading Contract Research Organization, gaining valuable perspective on the needs of this specialized industry and he also spent 10 years at General Electric, serving as the Global Industry Director for Life Sciences.

Reitter holds a Bachelor’s Degree in Marketing from Duquesne University and lives outside of Philadelphia with his wife and two daughters.

Nida Sayed is the Senior Manager of Upstream Process Development at the Boston Institute of Biotechnology, LLC – a global CDMO with operations in USA and Asia, and presence in Europe. Over her eight-year tenure with the company, she has led the development, optimization, and tech transfer of upstream processes spanning fermentation, cell culture and gene therapy. Her expertise covers the full development continuum, from early-stage high throughput screening and process development to late-stage process characterization and manufacturing support. Nida began her biopharma career at Lonza Biologics in 2011, where she where she gained foundational exposure to bio-pharma manufacturing. Since then, she has worked across an exceptional range of scales – from Ambr®15 micro-bioreactors to commercial scale production of 30,000L. She holds a B.S. from Savitribai Phule Pune University and an M.S. in Biotechnology from Northeastern University.

Sandra Bennun is an experienced leader in biomanufacturing, currently serving as Director of Biologics Research and Development at Merck global headquarters in the United States. She is responsible for leading a team accountable for early and late stage upstream and downstream process development, drive efforts to advance biological understanding, technology innovation, and process platforms. Prior to joining Merck, she held various positions in Biotechnology at Regeneron Pharmaceuticals, UniQure, BioMarin pharmaceuticals and Sandia National Laboratory. Sandra obtained her Ph.D. in Chemical Engineering with Designated Emphasis in Biotechnology from the University of California Davis and held a postdoctoral position at Johns Hopkins University.

https://www.linkedin.com/in/sandra-bennun/

Lindsey Daniel is the Global Operational Excellence (OE) Network Lead for Takeda’s Biologics Operating Unit, where she drives OE capability building, AOS maturity, and value-creation initiatives across five global manufacturing sites. She partners closely with senior leadership, finance, and site heads to deliver cost savings, strengthen operational performance, and build a culture of continuous improvement.

A licensed Professional Engineer, Lindsey holds Lean Six Sigma Black Belt certification and is currently pursuing her Master Black Belt. In 2025, she was honored with the Boston Business Journal’s 40 Under 40 award for her contributions to the life sciences community.

Anne Marie brings over 25 years of experience guiding global pharmaceutical biotechnology, and medical technology companies through complex operational change. As Accenture’s Americas Lead for Life Sciences Supply Chain and Operations and Industry X practice, Anne Marie oversees a diverse portfolio of client engagements focused on digital transformation, operational resilience, and patient-centric innovation. Her leadership spans the full value chain, from strategy through execution, across domains such as integrated planning, manufacturing, and logistics. Anne Marie is a key contributor to Accenture’s thought leadership in life sciences, shaping industry perspectives on topics such as digital manufacturing to contract manufacturing organization collaboration and autonomous supply chain.